Here's who's making the call for this year's Houston Innovation Awards. Photos courtesy

Ten Houstonians are in the hot seat for deciding the best companies and individuals in Houston's innovation ecosystem.

InnovationMap has announced its 2023 Houston Innovation Awards judging panel, which includes startup founders, nonprofit leaders, investors, corporate innovators, and more.

The 10 selected judges will evaluate applications from the nearly 400 nominations that were submitted this year. The judges will be using their expertise to evaluate the nominees' applications, which are due to InnovationMap by midnight on October 4.

Read about this year's judges below, and don't forget to secure your tickets to the November 8 event to see who the panel selects as the winners for the annual celebration of Houston innovation.

Natara Branch, CEO of Houston Exponential

Houston Exponential was founded to amplify and support the city's innovation ecosystem, and Natara Branch has been leading this initiative since appointed as CEO last year. For the second year, HX is partnering with InnovationMap on the Houston Innovation Awards.

Born in Germany and raised all around Texas, Branch — a University of Houston alumna — previously was the first African American woman to hold a vice president position at the NFL. Based in New York, she oversaw operations in various leadership roles at the NFL for over 18 years.

Barbara J. Burger, former Trailblazer Award recipient

Barbara J. Burger, former vice president of innovation at Chevron and president of Chevron Technology Ventures, was the inaugural recipient of the Trailblazer Award at the 2021 Houston Innovation Awards, which was previously called the InnovationMap Awards.

A self-proclaimed “graduate” from Chevron, she is senior adviser to Lazard, a member of the Greentown Labs Board of Directors, adviser to Syzygy Plasmonics, Epicore Biosystems, and Sparkz Inc., and several other energy transition and philanthropic roles. Burger holds a bachelor’s degree in chemistry from the University of Rochester, a doctoral degree in chemistry from the California Institute of Technology, and an academic honor MBA in finance from the University of California, Berkeley.

Devin Dunn, head of the Accelerator for Health Tech at TMC Innovation

As head of the Accelerator for Health Tech at the Texas Medical Center's Innovation Factory, Devin Dunn works hands on with startups — specifically to help them refine their business models and plan to scale — every day.

Prior to joining TMCi, Dunn was an early employee at a London-based digital health startup. She earned her bachelor’s degree in Biological Basis of Behavior and Healthcare Management from the University of Pennsylvania and received her Master’s in Public Health from the University of Texas Health Science Center.

Noah Fons, senior coordinator of regional economic development at the Greater Houston Partnership

Working within regional economic development at the Greater Houston Partnership, Noah Fons has the pulse on companies expanding to Houston. Previously, he worked at Houston Exponential, so he also understands Houston's evolving innovation ecosystem. He studied economics at Rice University.

Aziz Gilani, managing director at Mercury Fund

As managing director at Houston-based venture capital firm Mercury, Aziz Gilani focuses on investments in enterprise SaaS, Cloud, and data science startups. He's worked at the firm for over 15 years.

A Kauffman Fellows Program graduate, he received his bachelor's degree from the University of Texas and his MBA from Northwestern University’s Kellogg School of Management. Gilani also serves in advisory roles for the Mayor of Houston’s Tech and Innovation Council, Seed Accelerator Rankings, and SXSW Interactive and is an adjunct professor of entrepreneurship at Rice’s Jones Graduate School of Business where he teaches a course on venture capital.

Natalie Harms, editor of InnovationMap

For the third year, Natalie Harms will represent InnovationMap on the annual awards judging panel as the founding editor of InnovationMap the host of the Houston Innovators Podcast.

Recently named the editor of EnergyCapitalHTX, a newly launched sister site to InnovationMap focused on Houston's role within the energy transition, she reports on innovation, technology, energy transition — and their impact on the city of Houston. A Houston native, she's worked as a business journalist for almost a decade and has a degree in journalism from the University of Houston and a certificate in publishing from New York University.

Moji Karimi, co-founder and CEO of Cemvita Factory

Moji Karimi and his co-founder and sister, Tara Karimi, were honored at last year's Houston Innovation Awards as the winners of the Green Impact Business award. Cemvita Factory, their fast-growing startup, uses biotech to sustainably create materials to lower its customers carbon footprints.

Prior to launching Cemvita in 2018, Karimi held leadership roles at Weatherford and Biota Technology. He serves as a board member for CleanTX and adviser to Houston-based ComboCurve Inc.

Margarita Kelrikh, associate at Latham & Watkins

As associate in the Emerging Companies group at Latham & Watkins in Houston, Margarita Kelrikh has supported the firm's growing startup clients since her appointment last year. Prior to joining the firm, she held in-house counsel positions at a few companies, including WeWork.

She received her bachelor's degree at the University of Chicago and her law degree at Columbia School of Law.

Brad Rossacci, creative director at Accenture

Brad Rossacci is creative director at Accenture, where he's worked since 2018. He also co-founded and co-hosts the Curiosity Podcast. A Texas A&M University alumnus and self-proclaimed "rebellious optimist," Rossacci is passionate about Houston and innovation.

Maggie Segrich, co-founder of Sesh Coworking

As co-founder and CFO of inclusive coworking company, Sesh Coworking, Maggie Segrich is dedicated to supporting entrepreneurs of all backgrounds. Last year, Sesh Coworking won the Female-Founded Business category for the Houston Innovation Awards.

She serves as board member for Midtown Management District, where Sesh is located, and board chair for nonprofit, Magpies & Peacocks.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”